GSK plc

Publicly traded biopharmaceutical companies have faced a rough year for fundraising in 2025 with the amount of money raised across all financing types down significantly from 2024 levels during the

When clinical trial details are teased but deferred, investors will take a steer from the company management and key opinion leader commentaries. This has the potential for bias. Recent events around

The US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti

The decision by iTeos Therapeutics to wind down operations just a couple of weeks after the failure of its anti-TIGIT antibody belrestotug rather than hold on to considerable cash reserves until a buy